253196-36-0 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]amine hydrochloride is utilized as a research tool for the development of pharmaceuticals targeting central nervous system disorders. Its unique structure and properties contribute to the advancement of scientific understanding and the discovery of new therapeutic agents in this field.
Used in the Synthesis of Other Organic Compounds:
In addition to its role in pharmaceutical research, [(3-methyl-1,2,4-oxadiazol-5-yl)methyl]amine hydrochloride is also employed as a synthetic intermediate in the preparation of other organic compounds. Its versatility in chemical reactions makes it a valuable component in the synthesis of a variety of molecules with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 253196-36-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,3,1,9 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 253196-36:
(8*2)+(7*5)+(6*3)+(5*1)+(4*9)+(3*6)+(2*3)+(1*6)=140
140 % 10 = 0
So 253196-36-0 is a valid CAS Registry Number.
253196-36-0Relevant academic research and scientific papers
Aryl imidazole derivative and application thereof
-
Paragraph 0372; 0384-0387, (2021/06/23)
The invention relates to an aryl imidazole derivative and application thereof. The aryl imidazole derivative is a compound shown as a formula (I) in the description or pharmaceutically acceptable salt thereof. The invention also discloses application of the aryl imidazole derivative in preparation of drugs for treating cancers. The invention further discloses application of the aryl imidazole derivative in preparation of drugs for treating diseases caused by EGFR mutation.
PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS
-
Paragraph 0391; 0392, (2018/07/15)
The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
